fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

What are the implications of the NICE Quality Standards?

Written by | 9 Mar 2023

The updated and expanded NICE quality standards should be used in all care settings to audit and improve services for people with chronic heart failure, according to Dr… read more.

Why do we need NICE Quality Standards for chronic heart failure?

Written by | 8 Mar 2023

Dr Rani Khatib is a consultant pharmacist in cardiology and cardiovascular research and associate professor at the University of Leeds. As a member of the NICE Guideline Development… read more.

Alert banners dramatically increase prescribing rates of life-saving heart failure medication

Written by | 7 Mar 2023

An automated system that flags which patients could most benefit from an underused yet life-saving cardiology drug more than doubled new prescriptions, according to a pilot program test… read more.

Donor hearts can be reprogrammed with medication for longer storage, improved transplant outcomes

Written by | 16 Feb 2023

Hundreds of thousands of Americans with heart failure are sick enough to benefit from a transplant, yet only around 4,000 heart transplants are performed annually. One reason for… read more.

Dapagliflozin improves outcomes in heart failure among frail patients

Written by | 27 Apr 2022

Adjunctive dapagliflozin therapy appears to improve outcomes in heart failure patients without regard to frailty status at initiation of treatment. These findings appeared on April 26, 2022 in… read more.

Pilot study suggests artificial intelligence could help assess, improve heart transplant outcomes

Written by | 22 Mar 2022

Heart transplantation can be a lifesaving operation for patients with end-stage heart failure. However, many patients experience organ transplant rejection, in which the immune system begins attacking the… read more.

EMPEROR-Preserved phase III trial of Jardiance shows efficacy in heart failure – Eli Lilly + Boehringer

Written by | 1 Feb 2022

Jardiance (empagliflozin), from Eli Lilly and Boehringer, reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and slowed kidney function decline… read more.

Innovative approach brings cell-reprograming therapy for heart failure closer to reality

Written by | 19 Jan 2022

Not too long ago the idea of taking, for instance a skin cell and transforming it into a muscle cell was unthinkable. About 10 years ago, however, revolutionary… read more.

FDA approves Jardiance to treat adults living with heart failure with reduced ejection fraction – Boehringer Ingelheim + Eli Lilly

Written by | 27 Aug 2021

Jardiance (empagliflozin) 10 mg has been approved by the FDA to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with… read more.

Statin treatment linked to lower risk of cancer among heart failure patients

Written by | 3 Aug 2021

Treatment with statins of patients with heart failure is linked to a reduced risk of cancer, researchers reported on June 23, 2021 in the European Heart Journal. Lead investigator… read more.

European Commission approval for Verquvo to treat symptomatic chronic heart failure in adult patients with reduced ejection fraction – Bayer + Merck Inc.

Written by | 31 Jul 2021

Merck Inc., has announced that the European Commission (EC) has granted marketing authorization in the European Union (EU) for soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat). In the… read more.

Jardiance is EU approved for the treatment of heart failure with reduced ejection fraction – Boehringer + Eli Lilly

Written by | 30 Jun 2021

The European Commission has granted marketing authorization for Jardiance (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.